Results from Part-1 of ON-5001: A Multi-center, Dose Escalation and Dose Finding Phase 1 Trial of ONM-501, a Dual-Acting STING Agonist
Previous
Previous
ONM-421, a pH-responsive Polymer-Drug Conjugate Nanoparticle, Delivers MMAE to Solid Tumors and Shows Antigen-Independent Antitumor Efficacy in Mice
Next
Next